Hong Kong’s spinal muscular atrophy patients seek aid for injection therapy
Adults with spinal muscular atrophy face deteriorating health without subsidies for injections, despite new oral drug funding.
Patient advocates in Hong Kong are pressing the government to rectify a critical gap in healthcare funding for adults with spinal muscular atrophy (SMA). While a new subsidy program for oral medication for patients aged 25 and above launched in the first quarter of 2026, adult patients are still denied public funding for injection-based therapies. This disparity leaves many with deteriorating health, as their condition progresses without access to the full range of treatments their doctors may recommend.
The funding imbalance has a clear historical precedent. Hong Kong began subsidizing injection treatment for SMA patients under 18 back in 2018, later expanding it to other diseases. The oral medication was registered in 2021 for children, with the age-based subsidy for adults following years later. The Hong Kong Neuro-Muscular Disease Association argues this creates a two-tiered system, where treatment access is determined by age rather than clinical need. They are calling for parity, so adult patients can receive the therapy—injection or oral—that best suits their individual medical situation.
- Oral medication subsidies for SMA patients aged 25+ began in Q1 2026, but injection therapy remains unfunded for adults.
- Injection therapy has been publicly subsidized for SMA patients under 18 since 2018, highlighting an age-based coverage gap.
- Patient advocates demand equal subsidy access for both treatments, emphasizing choice should be based on individual medical need, not cost.
Why It Matters
This funding gap dictates quality of life and health outcomes for adults with a severe neuromuscular disease, based on an arbitrary age cutoff.